secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2024-10-03T23:59:59+00:00
Accession:  0001551152-24-000033
Event type: earnings
Sentiment:  negative
Materiality: 0.30
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie cuts 2024 adjusted EPS guidance by $0.04 on $82M Q3 IPR&D charge
-----------------------------------------------------------------------

- Q3 2024 acquired IPR&D & milestones expense of $82M pre-tax, reducing GAAP and adjusted EPS by $0.04.
- Q3 2024 adjusted diluted EPS guidance range now $2.88–$2.92, including the charge.
- Full-year 2024 adjusted diluted EPS guidance revised to $10.67–$10.87 from $10.71–$10.91.
- Guidance excludes any IPR&D expense beyond Q3 2024 due to forecasting uncertainty.
- Q3 2024 results are preliminary and subject to final closing procedures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115224000033/0001551152-24-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115224000033/abbv-20241003.htm
  HTML page:      https://secwatch.observer/filing/0001551152-24-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer